Citadel Advisors
VRDN icon

Citadel Advisors’s Viridian Therapeutics VRDN Stock Holding History

Citadel Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$573K Sell
31,200
-33,500
-52% -$540K ﹤0.01% 9527
2026
Q1 		$1.27M Buy
64,700
+57,900
+851% +$1.72M ﹤0.01% 7142
2025
Q4 		$212K Buy
+6,800
New +$187K ﹤0.01% 10926
2025
Q2 		– Sell
-45,100
Closed -$608K – 15303
2025
Q1 		$608K Sell
45,100
-102,500
-69% -$1.75M ﹤0.01% 8047
2024
Q4 		$2.83M Buy
147,600
+100,400
+213% +$2.18M ﹤0.01% 4935
2024
Q3 		$1.07M Buy
47,200
+42,300
+863% +$692K ﹤0.01% 6741
2024
Q2 		$63.7K Buy
4,900
+3,800
+345% +$52.6K ﹤0.01% 11493
2024
Q1 		$19.3K Sell
1,100
-800
-42% -$15.5K ﹤0.01% 13041
2023
Q4 		$41.4K Sell
1,900
-28,600
-94% -$451K ﹤0.01% 11983
2023
Q3 		$468K Sell
30,500
-18,900
-38% -$361K ﹤0.01% 8211
2023
Q2 		$1.18M Buy
49,400
+45,700
+1,235% +$1.17M ﹤0.01% 6127
2023
Q1 		$94.1K Sell
3,700
-400
-10% -$12.8K ﹤0.01% 11355
2022
Q4 		$120K Buy
+4,100
New +$94.5K ﹤0.01% 10967

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Citadel Advisors's VRDN Position: Q2 2026 in Review

Citadel Advisors reduced its Viridian Therapeutics (VRDN) stake by 98% in Q2 2026, selling an estimated $36.7M and leaving 41,303 shares worth $759K. The position accounts for ﹤0.01% of the portfolio, ranked #8878.

Citadel Advisors first reported a position in VRDN in Q4 2015 and has held it in 32 quarters since. The position peaked at $45.3M in Q1 2026. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Citadel Advisors held 41,303 shares of Viridian Therapeutics worth $759K as of Q2 2026.
  • Citadel Advisors sold 2,276,931 Viridian Therapeutics shares in Q2 2026, an estimated $36.7M.
  • Viridian Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8878 holding.
  • Citadel Advisors first reported a position in Viridian Therapeutics in Q4 2015 and has held it in 32 quarters since.
  • Citadel Advisors's Viridian Therapeutics position peaked at $45.3M in Q1 2026.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.